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Diabetes mellitus is an endocrine disease in which the pancreas does not produce suffi-
cient insulin or the body cannot effectively use the insulin it produces. Insulin therapy has
been the best choice for the clinical management of diabetes mellitus. The current insulin
therapy is via subcutaneous injection, which often fails to mimic the glucose homeostasis
that occurs in normal individuals. This provokes numerous attempts to develop a safe and
effective noninvasive route for insulin delivery. Oral delivery is the most convenient
administration route. However, insulin cannot be well absorbed orally because of its rapid
enzymatic degradation in the gastrointestinal tract. Therefore, nanoparticulate carriers
such as polymeric nanoparticles and micelles are employed for the oral delivery of insulin.
These nanocarriers protect insulin from degradation and facilitate insulin uptake via a
transcellular and/or paracellular pathway. This review article focuses on the application of
nanoparticles and micelles in insulin oral delivery. The recent advances in this topic are
also reviewed.
Copyright © 2015, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC.
 
Open access under CC BY-NC-ND license.1. Introduction
Diabetes mellitus is an endocrine disease in which the
pancreas does not produce sufficient insulin or the body
cannot efficiently use the insulin it produces [1,2]. There are
two basic types of diabetes: type I and type II. In type I dia-
betes, patients produce very little or no insulin. In type II
diabetes, patients cannot use insulin efficiently. The number
of diabetics will increase to 438 million worldwide by the yearf Pharmaceutical Sciences
in).
ministration, Taiwan. Publ2030, according to the World Health Organization (WHO) [3].
The primary goal for the treatment of type I and type II dia-
betes is to cure the symptoms related to hyperglycemia [4].
Insulin has an important role in diabetes treatment. Patients
with type I diabetes require daily injections of insulin to sur-
vive. Patients with type II diabetes may or may not require
exogenous insulin for treatment.
Human insulin is composed of 51 amino acid residues. Its
molecular formula is C257H387N65O77S6 and the corresponding
molecular weight is 5808 daltons. Human insulin consists of, School of Pharmacy, National Taiwan University, Number 33 Lin
ished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
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linked by disulfide bonds, which contain 21 amino acid resi-
dues and 30 amino acid residues, respectively. Insulin can be
isolated from human, porcine, bovine or sheep sources [5].
The blood glucose level in diabetic patients typically ranges
14e50 mmol/L [6]. By using exogenous insulin, the blood
glucose level is reduced and maintained within a narrow
range of 3.5e7.0 mmol/L. Insulin promotes the cellular uptake
of glucose and increases the synthesis of glycogen, fatty acids,
and proteins. Thus, the role of insulin is to convert excess
glucose into two storage formsdnamely, glycogen and tri-
glycerolsdand maintain glucose homeostasis [2]. Insulin
cannot be orally administered because it is unstable and
degraded by proteolytic enzymes in the gastrointestinal tract
[7]. The current insulin therapy is administered by subcu-
taneous injection, and the major adverse effects of this ther-
apy include hypoglycemia, allergy, insulin resistance, and
edema [8]. Multiple and frequent injections of insulin are
necessary but burdensome, which leads to poor patient
compliance. In addition, there is a risk of infection at the in-
jection site, especially for diabetic patients [6,9]. All of these
events have provoked numerous attempts to develop a safe
and effective noninvasive route for insulin delivery.
Oral, buccal, rectal, ocular, transdermal, intravaginal, pul-
monary, and nasal routes have been explored as noninvasive
routes for insulin delivery [6]. Among these delivery routes,
the administration of insulin by the oral route has been the
goal for many researchers because it minimizes the risk of
hypoglycemia while obtaining high patient compliance.
However, the delivery of insulin via the oral route is a chal-
lenge because of enzymatic instability and the poor absorp-
tion of insulin. Among the possible strategies to achieve
acceptable bioavailability, polymeric nanoparticles and mi-
celles have immense potential for insulin oral delivery
because of their nanosized feature and feasibility for surface
modification [9,10]. These nanocarriers possess several ad-
vantages over other conventional delivery systems (e.g., tab-
lets, capsules, beads, microparticles, and microemulsions)
[11]. The updates on the most promising advances of nano-
particles and micelles in insulin oral delivery are reviewed.2. Gastrointestinal hurdles in insulin oral
delivery
The administration of insulin by the oral route has been the
goal of many researchers. However, the oral bioavailability of
insulin is very poor. Macromolecular proteins normally
cannot cross the intestinal epithelium. They will instead be
degraded in the gastrointestinal tract before absorption [12].
Three main obstacles of insulin oral delivery need to be
considered: (1) the enzymes present in the gastrointestinal
tract, (2) the physiological barrier of the gastrointestinal tract,
and (3) the physicochemical property of insulin.
2.1. Enzymatic barrier
The gastrointestinal tract has a variety of enzymatic barriers
for insulin oral delivery. The insulin can be degraded by
intracellular enzymes (e.g., cathepsins), bacterial flora in themucus layer and in the epithelial cells of the intestine, and
proteolytic enzymes in the stomach and in the intestinal
lumen (e.g., pepsin, trypsin, and chymotrypsin) at the brush
border membrane (e.g., endopeptidases). These enzymes
denature protein drugs. Enzyme inhibitors can slow the in-
sulin degradation rate and increase the insulin that is avail-
able for absorption. Sodium cholate and aprotinin reportedly
act as enzyme inhibitors and improve insulin absorption in
rats [12,13]. However, the use of enzyme inhibitors in long-
term diabetic therapy remains questionable because of
possible toxicity.
2.2. Physiological barrier
The epithelial cells of the gastrointestinal tract are tightly
bound by tight junctions (i.e., the zonulae occludentes) in
which the outer surface of the intestinal epithelium is coated
bymucus and glycocalyx layers, and thus inhibits the passage
of insulin and its subsequent absorption [14]. Absorption may
be enhanced by using absorption enhancers such as bile salts,
trisodium citrates, EDTA, labrasol, and polymeric materials
(e.g., chitosan), which help to open the tight junctions of the
intestinal epithelium [13,15,16].
2.3. Physicochemical properties of insulin
The pore radius of the intestinalmucosa ranges 7e15 A˚, which
is an important barrier for macromolecular insulin trans-
location. The insulin molecules tend to aggregate at concen-
trations above 100nM. The transformation of the insulin
monomer with a molecular dimension of approximately
12e14 A˚ into a hexameric conformation impairs its transport
across the intestinal epithelium [7]. Temperature, solvents,
and additives may disrupt the primary amino acid sequence
and tertiary structure of insulin. The alteration in the func-
tional moiety or native charge of insulin has an impact on its
intestinal transport. At physiological pH, the carboxylic and
amino groups of insulin are entirely ionized, which results in a
zwitterionic configuration. It is likely to preclude insulin ab-
sorption from transcellular diffusion, unless the charges are
neutralized through ion pairs [7]. The large molecular size of
insulin nevertheless remains an obstacle to its absorption.
Modification of insulin chemical structure against possible
enzymatic degradation is an approach to raise its bioavail-
ability. A diacyl derivative of insulin has been shown to
maintain insulin biological activity and to increase its intes-
tinal absorption [17]. However, the application of this
approach to insulin is very challenged because of the struc-
tural complexity of proteins.3. Delivery systems for insulin oral delivery
The successful oral delivery of insulin requires considering
the physiological and biological stability of insulin in formu-
lations, in the gastrointestinal tract, and in the cytosol of
enterocytes. The barriers occurring principally in the oral
delivery of insulin can be overcome via incorporating func-
tional excipients in the dosage forms. The functional excipi-
ents act as a stabilizer, a protease inhibitor, a mucoadhesive
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stability and enhance its paracellular and/or transcellular
transport in terms of increasing its oral bioavailability.
Various dosage forms for insulin oral delivery such as nano-
particles, microparticles, hydrogels, tablets, and capsules
have been developed worldwide. Among these dosage forms,
nanoparticles have stability and the ability to undergo cellular
uptake, compared to the other delivery systems, when applied
in vivo [4,5]. Nanoparticles are feasible to transport and inter-
nalize through the intestinal epithelial membrane, which
changes the pharmacokinetic performance of insulin after
oral administration [8]. The performance of nanoparticles on
insulin oral delivery are affected by several parameters such
as the surface charge, particle size, polymer property, poly-
mereinsulin interaction, insulin loading, insulin release per-
formance, residence time at absorption site and the clearance
rate from the body [12].
3.1. Nanoparticles and micelles
Nanocarriers often refer to particles with a size of 1e100 nm.
Various nanocarriers for insulin delivery have been reported
such as polymeric nanoparticles, liposomes, solid lipid
nanoparticles, and micelles [2]. In this paper, the polymeric
nanoparticles and micelles are further discussed. Fig. 1 illus-
trates their basic conformations. Nanoparticles involve
nanospheres and nanocapsules. Nanospheres are a matrix
type of particle in which the drug is uniformly dispersed or
dissolved in the polymer matrix, whereas nanocapsules are
vesicles in which the drug core is surrounded by a polymeric
film [18]. Micelles are formed by amphiphilic copolymers
which self-assembled to nanosized aggregates above the
critical micellar concentration. The hydrophobic moiety
forms the core of micelles whereas the hydrophilic moiety
forms the corona in the shell of micelles. Micelles possess a
dynamic structure where the unimers of the amphiphilic
copolymer are interchangeable. There is a wide variety of
polymers and preparation methods applied to prepare
insulin-loaded nanoparticles and micelles (Table 1). The
mechanism of insulin delivered by nanoparticles andmicelles
is dominated by endocytosis, which is affected by the surface
properties of the nanocarriers [18].
3.2. Approaches for insulin oral delivery
Nanocarriers have immense potential for the effective oral
delivery of insulin. Designing nanocarriers to improve insulin
gastrointestinal absorption may be achieved via modifying
the polymer or nanoparticle surface property and applying anFig. 1 e Diagrammatic illustration of insulin-loaded
polymeric nanoparticles and micelles.
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bined with enzyme inhibitors or absorption enhancers, as
previously mentioned [12]. Table 2 summarizes these strate-
gies to enhance insulin absorption via using nanoparticle
delivery systems.
3.2.1. Polymeric nanocarrier approach
The polymeric nanoparticle is an approach to improve insulin
absorption from the gastrointestinal tract. Synthetic or natu-
ral polymeric materials modulate insulin release and conse-
quent pharmacological activity. Insulin-loaded nanoparticles,
which are prepared by using biodegradable polymers such as
poly(lactide-co-glycolide), polyanhydride, and polyalkyl
cyanoacrylate are absorbed from the intestinal epithelial cells
and transport insulin through the intestinal mucosa [12].
Some researchers have developed insulin-loaded nano-
particles using a biodegradable poly(ε-caprolactone) com-
bined with a nonbiodegradable acrylic polymer, Eudragit
RS100, which is effectively absorbed by the gastrointestinal
tract [19,20].
3.2.2. Enteric coating approach
The enteric coating technique has been applied to insulin oral
delivery in which the enteric coating polymers possess a pH-
dependent property [21]. Polyacrylic polymers (e.g., Eudragit
L100-55 and Eudragit S100) and cellulosic polymers (e.g.,
hydroxypropyl methyl cellulose phthalate) have been widely
used for this purpose [20,21]. The increase in insulin
bioavailability is achieved by filling the freeze-dried chitosan/
poly(g-glutamic acid) (CS/g-PGA) nanoparticles in enteric-
coated capsules [22]. The enteric-coated capsules protect the
insulin-loaded nanoparticles from acidic gastric fluid and
rapidly liberate insulin in the proximal segment of the small
intestine. Thus, the absorption of insulin into systemic cir-
culation is improved and the relative bioavailability of insulin
is increased.
3.2.3. Enzyme inhibitor approach
Insulin, which is a protein, is easily digested and inactivated
by digestive enzymes in the stomach after oral administra-
tion. Different protease inhibitors are administered alongwith
the nanoparticles to inhibit the activity of these enzymes [2,4].
Radwan and Aboul-Enein [23] report that the oral adminis-
tration of insulin-loaded poly(ethylcyanoacrylate) nano-
particles in the presence of protease inhibitors (e.g.,
glycerrizin, capric acid, deoxycholic acid, hydroxypropyl-b-
cyclodextrin, and aprotinin) efficiently reduces andmaintains
glucose level < 200 mg/dL (i.e., the normal glucose level after a
meal). Another approach to inhibit protease activity is by use
of cationic metal chelating agents such as diethylene-
triaminepentaacetic acid (DTPA) [24]. The addition of the
complexing agent DTPA in insulin nanoparticles demon-
strates a substantial protective effect against intestinal pro-
teases in which the DTPA binds to cofactors [e.g., calcium
(Ca2þ) and zinc (Zn2þ)] of the enzyme system and cause
structural alterations and the loss of enzymatic activity.
3.2.4. Permeation enhancers approach
The absorption of insulin from the gastrointestinal tract is
improved by the coadministration of permeation enhancers
j o u r n a l o f f o o d and d ru g an a l y s i s 2 3 ( 2 0 1 5 ) 3 5 1e3 5 8 355that widen the intercellular junction (e.g., paracellular
pathway) and/or perturbate the membrane phospholipids
(e.g., transcellularpathway) [4]. Permeationenhancersdwhich
include fatty acids, surfactants, Ca2þ-chelating agents, and
zonula occludens toxindare incorporated in the formulations.
Fatty acids such as sodium caprate and acyl carnitine improve
drugabsorptionvia the transientopeningof the tight junctions.
Surfactants enhance transcellular transport by disrupting the
lipid bilayer. Chelating agents form a complex with calcium
ions which rupture the tight junctions and assist the para-
cellular transport of insulin. Zonula occludens toxin similarly
transiently alters the tight junctions for the passage of insulin
through the mucosal barrier [25].
3.3. Modification of nanoparticles and micelles for
insulin oral delivery
For insulin oral delivery, the copolymers used to formmicelles
should (1) quickly self-assemble in water, (2) remain stable in
the gastrointestinal tract, (3) be nontoxic and biocompatible,
and (4) be easy to synthesize on a large scale [18]. Table 2 lists
some strategies to prepare stable micelles.
3.3.1. The micelle complex
This strategy involves introducing cross-linkable hydrophilic
groups into the hydrophobic polymer to form a stable micelle
system [18]. For example, the multifunctional, multiarmed
poly(ethylene glycol) is conjugated with biodegradable hy-
drophobic polymers to form an amphiphilic block copolymer
in which poly(ethylene glycol) branches create a cross-
linkable structure in the micelle system. The glucose-
responsive micelles are formed by the complexation of a
phenylboronic acid-containing block copolymer [e.g., poly(-
ethylene glycol)-b-poly(aspartic acid-co-aspartamidophe-
nylboronic acid)] and a glycopolymer [e.g., poly(aspartic acid-
co-aspartglucosamine)] [26]. The micelle complex has a vari-
ety of advantages such as it is stable against aggregation
because of the poly(ethylene glycol) shell, it is more sensitive
to the glucose level, and there is a fast response to glucose
change at the physiological pH.
3.3.2. Conjugation of functional moiety
This strategy involves the development of nanocarriers with a
permeation-enhancing property. The specific function moiety
is conjugated through the hydrophilic portion of the copol-
ymer. Zhang et al [27] and Yu et al [28] used arginine-rich
peptide modified N-octyl-N-arginine chitosan to improve in-
sulin oral absorption. Another method to improve insulin
absorption is to attach a specific targeting ligand to the
nanoparticle surface. Lectin is widely used for specific tar-
geting to intestinal epithelial cells. The developed lectin-
modified polystyrene nanoparticles successfully deliver in-
sulin from the oral administration route and achieve a two-
fold increase in nanoparticle absorption [12].
3.4. Factors affecting nanoparticle and micelle oral
absorption
Physicochemical and biological factors such as particle size,
surface charge, nanoparticle stability, the residence time ofnanoparticles at the absorption site, and the intestinal con-
tents may all affect nanoparticle or micelle absorption [29].
3.4.1. Particle size
Particle size is a crucial factor to determine the absorption,
distribution, and in vivo performance of nanoparticles. In
addition, particle size influences the insulin-loading capacity
and insulin release performance of nanoparticles. In general,
nanoparticles have a higher cellular uptake efficiency than
microparticles. Bakhru et al [29] and Panyam and Labhasetwar
[30] reported that the cellular uptake of poly(lactide-co-
glycolide) (PLGA) nanoparticles with a particle size of 100 nm
is 2.5-fold higher than 1-mmmicroparticles and six-fold higher
than 10-mm microparticles in Caco-2 cells. A similar phe-
nomenon has been observed in rats in vivo in which the
cellular uptake of PLGA nanoparticles is 15-fold and 250-fold
higher than 1-mm and 10-mm microparticles, respectively
[30]. A decrease of the particle size to < 1 mm increases particle
cellular uptake efficiency. Nanoparticles with a particle size <
100 nm are efficiently taken up in Peyer's patches, and then
absorbed into systemic circulation [12].
3.4.2. Surface charge
The surface chemistry of nanoparticles has a profound impact
on particles across the absorptive epithelium. Because the
intestinal cell membrane is negatively charged, positively
charged nanoparticles interact with the intestinal epithelium
more strongly, compared to negatively charged and un-
charged nanoparticles [29]. By contrast, nanoparticles pre-
pared by using more hydrophobic polymers [e.g., polystyrene,
poly(methyl methacrylate), and poly(hydroxybutyrate)]
demonstrate better absorption in Peyer's patches, compared
to using less hydrophobic polymers [e.g., poly(lactic acid) and
poly(lactide-co-glycolide)] [12].
3.4.3. Colloidal stability
Colloidal instability usually leads to nanoparticle and micelle
aggregation or flocculation [31]. Chemical stability is very
important, especially for nanocarriers bearing specific tar-
geting ligands. The stable colloidal system ensures the bind-
ing of nanocarriers to the specific receptor, followed by the
efficient internalization of the therapeutic agents into the
tumor cells [32].
3.5. Absorption mechanisms of nanoparticle and micelle
delivery systems
The intestinal epithelium controls the passage of drugs,
macromolecules, and particles. The surface area of the small
intestine is enlarged because of the villi and microvilli which
have a vital role in drug absorption in the gastrointestinal
tract. The mechanisms of translocation of nanoparticles and
micelles in the intestinal epithelium involve paracellular and/
or transcellular transport [33,34]. Fig. 2 illustrates the intesti-
nalmorphology and the translocation routes for nanoparticles
and micelles across the intestinal epithelium.
3.5.1. Paracellular pathway
The paracellular pathway is the preferred route for the
transport of hydrophilic drugs. However, it restricts the
(A)
(B)
(C)
(D)
Polymeric nanoparticles
Polymeric micelles
Enterocytes
Receptor
Blood vessel
Mucus layer
Fig. 2 e Schematic illustration of the different oral delivery
pathways of the insulin-loaded polymeric nanoparticles
and micelles: (A) receptor-mediated endocytosis, (B)
transcellular transport, (C) paracellular transport, and (D) M
cell-mediated transport.
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mately 1 nm because of a very small intercellular space and
because of the tight junctions between the epithelial cells
(pore diameter, 3e10 A˚) [34]. Therefore, polymeric nano-
particles usually cannot pass through the intestinal barrier via
the paracellular route. To improve their paracellular trans-
port, the tight junction must be opened reversibly by using
permeation enhancers such as cationic polymers (e.g., chito-
san and its derivatives), anionic polymers (e.g., polyacrylic
acid and its derivatives), or calcium chelators (e.g., ethyl-
enediaminetetraacetic acid). The width of the tight junction
opened by the enhancers is < 20 nm, which still limits the
transport of intact nanoparticles into the bloodstream if the
nanoparticle is > 20 nm [35]. In this situation, the nano-
particles must be destabilized and disintegrated in the inter-
cellular space when approaching the tight junction between
the epithelial cells so that the loaded drug is released and
permeated through the opened paracellular pathway. Sonaje
et al [35] report that insulin-loaded chitosan/poly(g-glutamic
acid) nanoparticles (CS/g-PGA NPs) are disintegrated at pH
7.2e7.4 because of the deprotonization of chitosan by which
the drug is released and transported through the opened tightTable 3 e The oral bioavailability of various insulin-loaded na
Nanoparticle formulation
Alginate/chitosan nanoparticles
PLGA/HPMCP-55 nanoparticles
PLGA/Eudragit RS100 nanoparticles in an enteric-coated capsule
Carboxylated chitosan-grafted poly(methylmethacrylate) nanoparticles
Alginate/dextran sulfate nanoparticles
Poly(ε-caprolactone)/Eudragit RS 100 nanoparticles
Chitosan/poly(g-glutamic acid) nanoparticles
Chitosan/poly(g-glutamic acid) nanoparticles in an enteric-coated capsu
Chitosan/poly(g-glutamic acid)-DTPA nanoparticles
Chitosan/sodium alginate nanoparticles
DTPA ¼ diethylenetriaminepentaacetic acid; PLGA ¼ poly(lactide-co-glycjunction. Permeation enhancers such as chitosan improve the
paracellular transport of drugs and vaccines via interaction of
these positively charged polymers with the negatively
charged cell membrane [36].
3.5.2. The transcellular pathway
The transcellular transport of nanoparticles occurs when the
nanoparticles are taken up by enterocytes or by the M cells of
Peyer's patches, and thus overcome presystemic hepatic
metabolism and enhance drug bioavailability. The transport
of nanoparticles through the cells can be effectively achieved
via active transcellular transport [37]. The active transcellular
transport involves phagocytosis, macropinocytosis, clathrin-
mediated endocytosis, and caveolin-mediated endocytosis
[34]. It has been reported that insulin-loaded hyaluronic acid
nanoparticles are transported across Caco-2 cell monolayer
primarily via a transcellular pathway; the apparent perme-
ability coefficient from the apical to the basolateral side shows
a two-fold increase, compared to an insulin solution [9,38].3.6. Bioavailability of insulin-loaded nanoparticles and
micelles
The effectiveness and safety of nanoparticulate delivery sys-
tems for insulin have been assessed for their intestinal ab-
sorption, bioavailability, physiological response, therapeutic
effect, and cytotoxicity. Table 3 [14,20,22,24,35,39e42] sum-
marizes the bioavailability of orally administered insulin-
loaded nanoparticles in diabetic rats. The oral delivery of in-
sulin by different kinds of polymeric nanoparticles generally
reveals 6e13% bioavailability [14,20,39e41]. For example, oral
delivery of insulin-loaded PLGA/Eudragit RS100 nanoparticles
in diabetic rats shows 13.2% bioavailability [14]. Several stra-
tegies have been applied to improve insulin oral bioavail-
ability. Sonaje et al [35] demonstrated 15% pharmacological
availability when orally administering insulin-loaded chito-
san/poly(g-glutamicacid) nanoparticles; its bioavailability was
further increased to 20% when the nanoparticles were loaded
in the enteric-coated capsule [22]. The oral intake of a capsule
containing insulin-loaded DTPA conjugated chitosan/poly(g-
glutamic acid) nanoparticles reveals 19.7 ± 1.3% bioavailability
[24]. Thus, DTPA acted as a complexing agent to disrupt in-
testinal tight junctions and inhibit intestinal proteases. Prusty
and Sahu [42] report that the oral bioavailability of insulin-noparticle formulations in diabetic rats.
Dose (IU/kg) Bioavailability (%) Refs
50 5.1 ± 2.1 [39]
50 6.27 [20]
50 9.2 [20]
25 9.7 [40]
50 10.7 [41]
50 13.2 [14]
30 15 [35]
le 30 20 [22]
30 19.7 ± 1.3 [24]
10 43.6 [42]
olide).
j o u r n a l o f f o o d and d ru g an a l y s i s 2 3 ( 2 0 1 5 ) 3 5 1e3 5 8 357loaded chitosan/sodium alginate nanoparticles is 43.6%
(relative to insulin injection) in which chitosan acts as a
mucoadhesive agent to transiently and reversibly open the
tight junctions between epithelial cells and thereby promi-
nently enhance insulin absorption [42].3.7. Possible toxicity of nanoparticles in use and in
future study
Several researchers have proven that nanocarriers adminis-
tered daily to patients are safe, nontoxic, biocompatible, and
biodegradable, and they evoke reproducible biological effects.
By contrast, there are some literature reports on the toxico-
logical impacts of nanocarriers on human health. Recent
literature suggests that the cytotoxicity of nanoparticles is
associated with oxidative stress and with proinflammatory
gene activation; however, the exact underlying mechanism
remains unknown [43]. Therefore, there is a need to consider
the usefulness of nanocarriers and the unpredictable and
adverse consequences of nanocarriers to human health.
Nanocarriers have different properties from their bulk
conformation, which allows them to pass through cell mem-
branes and biological barriers at the cellular level in tissues
and organs. It is widely known that the nanocarriers toxicity
depends on several physiochemical parameters such as par-
ticle size, shape, surface charge, composition, and subsequent
stability of the nanocarriers [44,45]. In addition, the adminis-
tration dose, administration route, and tissue distribution
seem to be important factors relevant to nanocarrier cyto-
toxicity. For the safe development and safe use of nano-
particles, investigations regarding the cellular toxicity of
nanocarriers has become more important and necessary.4. Conclusion and future perspectives
The protection of insulin from the harsh gastrointestinal
environmentmakes nanoparticles andmicelles an alternative
promising delivery system for insulin. Recent overall findings
reveal that advances in insulin oral delivery mostly focus on
the development of the following: (1) biocompatible polymers
withmucoadhesive and absorption-enhancing properties [46],
(2) nanocarriers with enhanced transport ability [35], and (3)
nanoparticles bearing specific ligands for effective oral de-
livery of insulin [12]. All of these advances highlight the
importance of designing nanomedicines for insulin. Many
studies indeed demonstrate that polymeric nanoparticles and
micelles enhance insulin oral bioavailability in the preclinical
animal stage. Whether these insulin-loaded nanocarriers can
be launched in the market in the future still has many chal-
lenges. Therefore, continuous investigation and optimization
of nanoparticle-based delivery systems for insulin oral de-
livery in diabetics are anticipated.Conflicts of interest
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